[HTML][HTML] Fel d 1–derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study
D Patel, P Couroux, P Hickey, AM Salapatek… - Journal of Allergy and …, 2013 - Elsevier
BACKGROUND: Allergic rhinoconjunctivitis is an increasingly common source of morbidity,
with sensitivity to cats accounting for 10% to 15% of disease burden. Allergy to cats is also a
major risk factor for the development of asthma. OBJECTIVES: We sought to probe the
persistence of the treatment effect of a novel Fel d 1–derived peptide antigen desensitization
(Cat-PAD) 1 year after the start of treatment in subjects with cat allergy–induced
rhinoconjunctivitis after standardized allergen challenge. METHODS: In a randomized …
with sensitivity to cats accounting for 10% to 15% of disease burden. Allergy to cats is also a
major risk factor for the development of asthma. OBJECTIVES: We sought to probe the
persistence of the treatment effect of a novel Fel d 1–derived peptide antigen desensitization
(Cat-PAD) 1 year after the start of treatment in subjects with cat allergy–induced
rhinoconjunctivitis after standardized allergen challenge. METHODS: In a randomized …